HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Obama Stocks    My Account    Help    
Connect with Zacks on Facebook
Quote:
Login
Search:

Commentary BETA - Give us your feedback
Analyst Blog

Abbott Labs Deserves Its Premium

By: Brian Marckx, CFA
December 22, 2008 | Comments: 0
Recommended this article (0)
ABT
Print    Share

Abbott Laboratories (ABT - Analyst Report) discovers, develops, manufactures and sells a diversified line of healthcare products. We expect double-digit EPS growth over the next few years driven by strong sales of Humira and the company's rapidly growing vascular business.

Several new drug applications have recently been filed with the FDA which should accelerate sales in the pharmaceutical business. Based on our model, the company is expected to deliver high single-digit EPS growth through the end of 2013.

We believe ABT possesses a low-risk profile and will continue to trade at an industry premium. Accordingly, we reiterate our Buy recommendation with a price target of $65.

Jason Napodano, CFA contributed to this report.

Read the full analyst report on ABT



Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (0)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!

More Zacks Resources

Market Summary Jul 04, 2009 19:15 pm ET
DJIA 8280.74  -223.32 -2.63%
NASD 1796.52  -49.20 -2.67%
S&P 500 896.42  -26.91 -2.91%
Sponsored Links
Commentary Beta
GIVE US YOUR FEEDBACK